Breaking News, Collaborations & Alliances

Alcami, PharmaTher Enter Manufacturing Agreement

U.S.-based CDMO to manufacture PharmaTher’s ketamine products for FDA Phase 3 clinical studies and global commercialization.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The clinical-stage psychedelics biotech company PharmaTher has entered into an agreement with global pharmaceutical contract development and manufacturing organization (CDMO) Alcami for the clinical and commercial manufacturing of its proprietary ketamine products.    PharmaTher is focused on building a specialty ketamine-based product pipeline to support its internal product pipeline, including rare and near-rare neurological disorders such as Parkinson’s disease and ALS (Lou Gehrig’s disease)....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters